Quetiapine probably leads to lower extrapyramidal effects compared with typical antipsychotics (moderate certainty).
Formoterol showed no clear difference in patients with an exacerbation requiring hospitalisation compared with short‐acting beta2‐agonist (moderate certainty).
Formoterol probably leads to lower patients with an exacerbation requiring a course of oral… compared with short‐acting beta2‐agonist (moderate certainty).
Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).
Formoterol showed no clear difference in patients with a serious adverse event (all cause) compared with short‐acting beta2‐agonist (low certainty).
Formoterol showed no clear difference in patients with a serious adverse event (asthma related) compared with short‐acting beta2‐agonist (low certainty).
Formoterol may leads to higher withdrawals (any reason) compared with short‐acting beta2‐agonist (low certainty).
CLOZAPINE probably leads to lower relapse ‐ short term compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
CLOZAPINE probably leads to lower global impression: 1. Not clinically improved ‐ short term compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
CLOZAPINE showed no clear difference in adverse effects 1. Blood problems compared with TYPICAL ANTIPSYCHOTICS; GRADE not reported.
CLOZAPINE probably leads to higher adverse effects 4. Salivation ‐ too much compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
CLOZAPINE probably leads to higher adverse effects 5. Weight gain compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
CLOZAPINE showed no clear difference in unable to work compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
CLOZAPINE probably leads to higher adverse effects: 1. Blood problems ‐ decreased white cell count compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).